Literature DB >> 23809106

Animal models for thrombotic thrombocytopenic purpura.

K Vanhoorelbeke1, S F De Meyer.   

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a puzzling disorder in many ways. The disease is difficult to diagnose as analogous symptoms are also found in other microangiopathic disorders. Although ADAMTS13 deficiency is generally required to develop TTP, only some patients with severe ADAMTS13 deficiency do spontaneously develop this disease. It is therefore assumed that environmental and/or genetic factors are needed to cause acute TTP. Nevertheless, acute TTP-like symptoms have also been observed in patients with moderate or normal levels of ADAMTS13. The development of animal models for TTP has allowed a closer look at the specific need for ADAMTS13 deficiency and the necessity for additional triggers in the pathophysiology of TTP. Mouse models for congenital TTP and a baboon model for acquired TTP have been generated. These animal models have also proven to be extremely valuable in developing new treatment strategies for TTP. In the current review, we discuss current animal models for TTP, what we have learned from them and how they were used to test new treatment strategies.
© 2013 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  ADAMTS13 protein; animal models; hemolytic anemia; thrombocytopenia; thrombotic thrombocytopenic purpura; von Willebrand factor

Mesh:

Year:  2013        PMID: 23809106     DOI: 10.1111/jth.12255

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  12 in total

1.  Transfer of ADAMTS13 antibody-mediated thrombotic thrombocytopenic purpura via kidney transplantation.

Authors:  Lara Zafrani; Charlotte Dekimpe; Bérangère S Joly; Elien Roose; Fabienne Fieux; Elie Azoulay; Marie-Noëlle Peraldi; Antoine Durrbach; Paul Coppo; Karen Vanhoorelbeke; Agnès Veyradier
Journal:  Haematologica       Date:  2019-02-28       Impact factor: 9.941

2.  Understanding therapeutic targets in thrombotic thrombocytopenic purpura.

Authors:  Bérangère S Joly; Karen Vanhoorelbeke; Agnès Veyradier
Journal:  Intensive Care Med       Date:  2017-01-23       Impact factor: 17.440

3.  ADAMTS13 Endopeptidase Protects against Vascular Endothelial Growth Factor Inhibitor-Induced Thrombotic Microangiopathy.

Authors:  Luise Erpenbeck; Melanie Demers; Zsuzsanna K Zsengellér; Maureen Gallant; Stephen M Cifuni; Isaac E Stillman; S Ananth Karumanchi; Denisa D Wagner
Journal:  J Am Soc Nephrol       Date:  2015-06-02       Impact factor: 10.121

4.  ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 2. Pathogenicity in an animal model.

Authors:  Eric M Ostertag; Khalil Bdeir; Stephen Kacir; Michelle Thiboutot; Gayathri Gulendran; Lenka Yunk; Vincent M Hayes; David G Motto; Mortimer Poncz; X Long Zheng; Douglas B Cines; Don L Siegel
Journal:  Transfusion       Date:  2016-04-04       Impact factor: 3.157

5.  Formation and Resolution of Pial Microvascular Thrombosis in a Mouse Model of Thrombotic Thrombocytopenic Purpura.

Authors:  Reheman Adili; Michael Holinstat
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-07-25       Impact factor: 8.311

6.  Platelet surface-associated activation and secretion-mediated inhibition of coagulation factor XII.

Authors:  Natalia V Zakharova; Elena O Artemenko; Nadezhda A Podoplelova; Anastasia N Sveshnikova; Irina A Demina; Fazly I Ataullakhanov; Mikhail A Panteleev
Journal:  PLoS One       Date:  2015-02-17       Impact factor: 3.240

7.  Re-examination of 30-day survival and relapse rates in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.

Authors:  Cassiana E Bittencourt; Jennifer P Ha; Robert W Maitta
Journal:  PLoS One       Date:  2015-05-22       Impact factor: 3.240

8.  Generation of Anti-Murine ADAMTS13 Antibodies and Their Application in a Mouse Model for Acquired Thrombotic Thrombocytopenic Purpura.

Authors:  Louis Deforche; Claudia Tersteeg; Elien Roose; Aline Vandenbulcke; Nele Vandeputte; Inge Pareyn; Elien De Cock; Hanspeter Rottensteiner; Hans Deckmyn; Simon F De Meyer; Karen Vanhoorelbeke
Journal:  PLoS One       Date:  2016-08-01       Impact factor: 3.240

Review 9.  Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers.

Authors:  Johana Hrdinová; Silvia D'Angelo; Nuno A G Graça; Bogac Ercig; Karen Vanhoorelbeke; Agnès Veyradier; Jan Voorberg; Paul Coppo
Journal:  Haematologica       Date:  2018-04-19       Impact factor: 9.941

10.  Reduced cleavage of von willebrand factor by ADAMTS13 is associated with microangiopathic acute kidney injury following trauma.

Authors:  William E Plautz; Shannon H Haldeman; Mitchell R Dyer; Jason L Sperry; Francis X Guyette; Patricia A Loughran; Jurgis Alvikas; Adnan Hassoune; Lara Hoteit; Nijmeh Alsaadi; Brian S Zuckerbraun; Marian A Rollins-Raval; Jay S Raval; Roberto I Mota; Matthew D Neal
Journal:  Blood Coagul Fibrinolysis       Date:  2022-01-01       Impact factor: 1.061

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.